Iopentol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 534935

CAS#: 89797-00-2

Description: Iopentol is a bioactive chemical.


Chemical Structure

img
Iopentol
CAS# 89797-00-2

Theoretical Analysis

MedKoo Cat#: 534935
Name: Iopentol
CAS#: 89797-00-2
Chemical Formula: C20H28I3N3O9
Exact Mass: 834.90
Molecular Weight: 835.169
Elemental Analysis: C, 28.76; H, 3.38; I, 45.59; N, 5.03; O, 17.24

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Iopentol

IUPAC/Chemical Name: 1,3-Benzenedicarboxamide, 5-(acetyl(2-hydroxy-3-methoxypropyl)amino)-N,N'-bis(2,3-dihydroxypropyl)-2,4,6-triiodo-

InChi Key: IUNJANQVIJDFTQ-UHFFFAOYSA-N

InChi Code: InChI=1S/C20H28I3N3O9/c1-9(29)26(5-12(32)8-35-2)18-16(22)13(19(33)24-3-10(30)6-27)15(21)14(17(18)23)20(34)25-4-11(31)7-28/h10-12,27-28,30-32H,3-8H2,1-2H3,(H,24,33)(H,25,34)

SMILES Code: O=C(C1=C(I)C(N(C(C)=O)CC(O)COC)=C(I)C(C(NCC(O)CO)=O)=C1I)NCC(O)CO

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 835.17 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Berg KJ, Kolmannskog F, Lillevold PE, Nordal KP, Ressem L, Rootwelt K, Svaland MG. Iopentol in patients with chronic renal failure: its effects on renal function and its use as glomerular filtration rate parameter. Scand J Clin Lab Invest. 1992 Feb;52(1):27-33. doi: 10.3109/00365519209085437. PMID: 1594886.


2: Vik-Mo H, Danielsen R, Skinningsrud K, Haider T, Bjørkhaug A. Cardiovascular and electrocardiographic effects of iopentol in left ventricular angiography. Comparison of the low-osmolar, non-ionic iopentol (Imagopaque 350) and the hyper-osmolar, ionic metrizoate meglumine-Na-Ca (Isopaque Coronar 370) in patients with coronary heart disease. Eur Radiol. 1997;7 Suppl 4:S156-61. doi: 10.1007/pl00006885. PMID: 9204361.


3: Ericsson K, Bjartveit K. Iopentol (Imagopaque 300 and 350) compared with iohexol (Omnipaque 300 and 350) in cerebral and aortic arch angiography. A clinical trial assessing adverse events and diagnostic information. Eur Radiol. 1997;7 Suppl 4:S152-5. doi: 10.1007/pl00006884. PMID: 9204360.


4: Stake G, Monclair T, Berg KJ, Rootwelt K, Brekke O. Effect of iopentol on renal function and its use for calculation of glomerular filtration rate in children. Acta Radiol. 1995 Jan;36(1):64-8. PMID: 7833171.


5: Kunnen M, De Greef D, Skinningsrud K. Iopentol (Imagopaque 350) compared with iohexol (Omnipaque 350) in pediatric cardioangiography. A clinical trial assessing adverse events, ECG, blood pressure and diagnostic information. Eur Radiol. 1997;7 Suppl 4:S123-6. doi: 10.1007/pl00006877. PMID: 9204353.


6: Valentine A, Jakobsen JA, Klaveness AJ. Iopentol (Imagopaque 350) compared with diatrizoate (Urografin 370) in cerebral CT. A clinical trial assessing immediate and late (7 days) adverse events and diagnostic information (visualization quality and Hounsfield unit measurements). Eur Radiol. 1997;7 Suppl 4:S145-8. doi: 10.1007/pl00006882. PMID: 9204358.


7: Piéchaud JF, Iserin L, Aggoun Y, Kachaner J, Skinningsrud K. Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in pediatric angiocardiography. A clinical trial assessing adverse events, ECG and diagnostic information. Eur Radiol. 1997;7 Suppl 4:S127-30. doi: 10.1007/pl00006878. PMID: 9204354.


8: Sayegh N, Porée C, Baraton J, Skinningsrud K, Nantois C, Lallemand D. A double-blind CT study comparing the safety and efficacy of iopentol and ioxaglate in paediatric patients. Eur Radiol. 1996;6(4):574-7. doi: 10.1007/BF00182498. PMID: 8798046.


9: Kruse A, Brock A, Rodenberg J, Nowakowska-Duawa E, Bjartveit K. Iopentol (Imagopaque 250) compared with diatrizoate (Urografin 219) in endoscopic retrograde cholangio-pancreatography (ERCP). A clinical trial assessing safety (adverse events and S-pancreatic iso-amylase) and diagnostic information (VAS). Eur Radiol. 1997;7 Suppl 4:S131-4. doi: 10.1007/pl00006879. PMID: 9204355.


10: Sortland O, Johansen JG, Oksendal AN, Waaler A. Iopentol in urography. A clinical comparison between iopentol and metrizoate including delayed reactions. Acta Radiol. 1992 Jul;33(4):368-73. PMID: 1633050.


11: Berg A, Fagervoll R, Aulie Michelet A, Dugstad H. Synthesis, analysis and toxicity of some compounds which may be formed during the synthesis of iopentol. Acta Radiol Suppl. 1987;370:27-31. PMID: 2980307.


12: Encina JL, Martí-Bonmatí L, Ronchera-Oms CL, Rodríguez V. Iopentol (Imagopaque 300) compared with iopromide (Ultravist 300) in abdominal CT. A multi-centre monitoring trial assessing adverse events and diagnostic information--results from 518 patients in Spain. Eur Radiol. 1997;7 Suppl 4:S115-9. doi: 10.1007/pl00006875. PMID: 9204351.


13: Spitzer S, Münster W, Sternitzky R, Bach R, Jung F. Influence of Iodixanol-270 and Iopentol-150 on the microcirculation in man: influence of viscosity on capillary perfusion. Clin Hemorheol Microcirc. 1999;20(1):49-55. PMID: 11185684.


14: Mathias K, Kempkes U, Schmiedel E. Semiquantitative Erfassung von Schmerz- und Hitzesensationen zur Beurteilung von Kontrastmitteln bei der Becken/Beinangiographie. Intraindividuelle Doppelblindstudie mit lomeprol 350 und lopentol 350 [Semiquantitative detection of pain and heat sensations in evaluation of contrast media in pelvic/leg angiography. Intraindividual double- blind study with iomeprol 350 and iopentol 350]. Radiologe. 1996 Feb;36(2):164-8. German. doi: 10.1007/s001170050054. PMID: 8867434.


15: Cheng KT. N,N´-Bis(2,3-dihydroxypropyl)-5-[N-(2-hydroxy ethyl-3-methoxypropyl)-acetamidol]-2,4,6-triiodoisophthalamide. 2006 Mar 6 [updated 2008 Mar 4]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004–2013. PMID: 20641971.


16: Svaland MG, Kolmannskog F, Lillevold PE, Nordal KP, Ressem L, Berg KJ. Pharmacokinetics of iopentol in patients with chronic renal failure. Acta Radiol. 1992 Sep;33(5):482-4. PMID: 1389660.


17: Jung F, Mrowietz C, Gerk U, Franke RP. Influence of a radiographic contrast media (Iopentol) with different viscosities on capillary perfusion in patients with coronary artery disease. Clin Hemorheol Microcirc. 2013;53(1-2):201-8. doi: 10.3233/CH-2012-1557. PMID: 22596231.


18: Aulie Michelet A. Effects of intravascular contrast media on blood-brain barrier. Comparison between iothalamate, iohexol, iopentol and iodixanol. Acta Radiol. 1987 May-Jun;28(3):329-33. PMID: 2958041.


19: Berg A, Fagervoll R. Synthesis, isomerism and characterization of iopentol. Acta Radiol Suppl. 1987;370:13-21. PMID: 2980305.


20: Almén T. Effects of iodixanol, iopentol, iohexol and metrizoate on femoral blood flow after injection into the femoral artery of the dog. Acta Radiol Suppl. 1987;370:69-72. PMID: 2980316.